Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib-Reference-Cited by-同舟云学术

Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib

Published:2020-11-20 Issue:4 Volume:62 Page:874-882
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Shen Kai-ni¹,Miao Hui-lei¹,Zhang Cong-li¹,Feng Jun¹,Zhang Lu¹,Cao Xin-xin¹^ORCID,Zhou Dao-bin¹,Wei Su²,Li Jian¹^ORCID

Affiliation:

1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China;

2. Department of Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China

Funder

National Natural Science Foundation of China

Beijing Natural Science Foundation

Capital Health Research and Development of Special Fund

CAMS Innovation Fund for Medical Sciences

National Key Research and Development Program of China

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1849675